US2011118315A1PendingUtilityA1

5-lipoxygenase-activating protein (flap) inhibitors

48
Assignee: HUTCHINSON JOHN HPriority: Nov 4, 2005Filed: Jan 24, 2011Published: May 19, 2011
Est. expiryNov 4, 2025(expired)· nominal 20-yr term from priority
Inventors:John Howard HutchinsonPetpiboon PrasitMark MoranJillian F. EvansYiwei LiJasmine Eleanor ZunicJeannie M. ArrudaNicholas Simon StockBrian Andrew StearnsMustapha HaddachJeffrey Roger Roppe
A61P 9/14A61P 43/00A61P 9/00A61P 9/08A61P 37/08A61P 9/02A61P 9/12A61P 9/10A61P 35/00A61P 9/06A61P 39/02A61P 35/02A61P 25/16A61P 25/00A61P 25/04A61P 29/00A61P 27/02A61P 25/06A61P 25/28A61P 3/00A61P 27/16A61P 25/02A61P 17/02A61P 1/04A61P 11/06A61P 17/06A61P 11/02A61P 11/00A61P 1/00A61P 17/00A61P 19/08A61P 13/10A61P 19/02A61P 17/04C07D 413/14C07D 401/14C07D 403/10C07D 471/04C07D 209/00A61K 31/415C07D 417/12C07D 417/14C07D 401/12
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

Claims

exact text as granted — not AI-modified
1 . A method for treating inflammation in a human comprising administering a therapeutically effective amount of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid or a pharmaceutically acceptable salt or a pharmaceutically acceptable N-oxide thereof, to the human in need. 
     
     
         2 . The method according to  claim 1 , wherein 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid is present in the form of a sodium salt. 
     
     
         3 . A method for treating respiratory disease in a human comprising administering a therapeutically effective amount of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid or a pharmaceutically acceptable salt or a pharmaceutically acceptable N-oxide thereof, to the human in need. 
     
     
         4 . The method according to  claim 3 , wherein the respiratory disease is asthma. 
     
     
         5 . The method according to  claim 3 , wherein the respiratory disease is chronic obstructive pulmonary disease. 
     
     
         6 . The method according to  claim 3 , wherein the respiratory disease is rhinitis. 
     
     
         7 . The method according to  claim 3 , wherein 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid is present in the form of a sodium salt. 
     
     
         8 . The method according to  claim 7 , wherein the respiratory disease is asthma. 
     
     
         9 . The method according to  claim 7 , wherein the respiratory disease is chronic obstructive pulmonary disease. 
     
     
         10 . The method according to  claim 7 , wherein the respiratory disease is rhinitis 
     
     
         11 . A method for treating cardiovascular disease in a human comprising administering a therapeutically effective amount of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid or a pharmaceutically acceptable salt or a pharmaceutically acceptable N-oxide thereof, to the human in need. 
     
     
         12 . The method according to  claim 11 , wherein 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid is present in the form of a sodium salt.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.